Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Family matters: How MYC family oncogenes impact small cell lung cancer

24 Jul 2017

Abstract excerpt

Small cell lung cancer (SCLC) is one of the most deadly cancers and currently lacks effective targeted treatment options. Recent advances in the molecular characterization of SCLC has provided novel insight into the biology of this disease and raises hope for a paradigm shift in the treatment of SCLC. We and others have identified activation of MYC as a driver of susceptibility to Aurora kinase inhibition in SCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28737478
DOI: 10.1080/15384101.2017.1339849

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Family matters: How MYC family oncogenes impact small cell lung cancerPMID 28737478Read ↗

The molecular pathogenesis of small cell lung cancerSemantic proximity Read ↗

A framework for identification of actionable cancer genome dependencies in small cell lung cancerSemantic proximity Read ↗

MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerSemantic proximity Read ↗

FOXM1 targeting alters AURKB activity and reshapes antitumor immunity to curb the progression of small cell lung cancerSemantic proximity Read ↗

MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung CancerSemantic proximity Read ↗

C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug TargetSemantic proximity Read ↗

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Semantic proximity Read ↗

Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancerSemantic proximity Read ↗

The Expression and Prognosis for Aurora kinases in Human non-small cell lung cancerSemantic proximity Read ↗

Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung CancerSemantic proximity Read ↗

Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancerSemantic proximity Read ↗

Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene ExpressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.